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Neisseria meningitidis is a leading cause of bacte-
rial meningitis worldwide. We studied the potential
of synthetic lipopolysaccharide (LPS) inner core
structures as broadly protective antigens against
N. meningitidis. Based on the specific reactivity of
human serum antibodies to synthetic LPS cores,
we selected a highly conserved LPS core tetrasac-
charide as a promising antigen. This LPS inner core
tetrasaccharide induced a robust IgG response in
mice when formulated as an immunogenic glycocon-
jugate. Binding of raised mouse serum to a broad
collection of N. meningitidis strains demonstrated
the accessibility of the LPS core on viable bacteria.
The distal trisaccharide was identified as the crucial
epitope, whereas the proximal Kdo moiety was im-
munodominant and induced mainly nonprotective
antibodies that are responsible for lack of functional
protection in polyclonal serum. Our results identified
key antigenic determinants of LPS core glycan and,
hence, may aid the design of a broadly protective im-
munization against N. meningitidis.
INTRODUCTION
N. meningitidis is an encapsulated human bacterial pathogen
that causes meningitis and sepsis worldwide. Vaccines based
on capsular polysaccharides are available against invasive
meningococcal serogroups A, C, W, and Y, but not for B, as its
capsule consists of autoantigenic a-(2/8)-polysialic acid (Finne
et al., 1983; Granoff, 2010). Thus, vaccines based on noncapsu-
lar antigens are needed to limit N. meningitidis B infections, with
globally 20,000 to 80,000 cases per year, especially in developed
countries (Hedari et al., 2014). Recently, a multicomponent
vaccine 4CMenB, based on recombinant proteins and outer
membrane vesicles, was developed by Novartis (Bexsero) that38 Chemistry & Biology 22, 38–49, January 22, 2015 ª2015 Elsevieris protective against 88% of N. meningitidis B strains (Frosi
et al., 2013). The composition of 4CMenB was adjusted to target
serogroup B strains. The vaccine components of 4CMenB are
present in N. meningitidis isolates of other serogroups and
bear the potential to protect against non-B serogroups (Hong
et al., 2013). Alternatively, lipopolysaccharide (LPS) presents a
promising subcapsular antigen that might elicit broader reac-
tivity against allN. meningitidis strains. The LPS is also called lip-
ooligosaccharide because of the absence of O-polysaccharide
and is anchored via lipid A in the outer membrane (Nikaido,
2003; Raetz and Whitfield, 2002). The meningococcal LPSs
only show a core oligosaccharide that is subdivided into inner
and outer cores. The inner core consists of two Kdo (3-deoxy-
a-D-manno-oct-2-ulosonic acid) and two Hep (L-glycero-D-
manno-heptose) residues (Figure 1). The LPS outer core con-
tains mostly of hexoses building up variable a chain extensions
fromHepI (Figure 1, inset). In addition, b chain and g chain exten-
sions and a phosphoethanolamine (PEtN) modification on HepII
are possible. These diverse outer core compositions determine
12 distinct immunotypes of N. meningitidis (L1–12) (Choudhury
et al., 2008; Nikaido, 2003; Plested et al., 1999). The immunotype
expression is subjected to phase variation (Berrington et al.,
2002; Zhu et al., 2002). L1–L8 immunotypes are associated
with serogroups B and C, and L9 immunotype is common in se-
rogroups A, B, and C, whereas L10–L12 immunotypes are found
in serogroup A (Mistretta et al., 2010). In contrast, the LPS inner
core is highly conserved because inner core glycosyltransferase
genes are not subjected to phase variation (Kahler et al., 2005).
The potential of the LPS inner core as subcapsular antigen
was evaluated earlier using purified LPS from a DgalE mutant
of the widely studiedN. meningitidis B strain MC58 (immunotype
L3; Figure 1, inset). The DgalE LPS shows an inner core with an a
chain extension of b-(1/4)-linked Glc on HepI, with a-(1/2)-
linked GlcNAc as a g chain extension and PEtN modification at
the 3-position of HepII. A monoclonal antibody (mAb) B5 raised
against the purifiedDgalE LPS bound to 76%ofN.meningitidisB
strains and to 70%of a collection ofN. meningitidis strains of se-
rogroups A, C,W, X, Y, and Z. All these strains share the common
DgalE LPS core epitope with PEtN at the 3-position of HepII
(Plested et al., 1999). mAbB5 has been shown to promote serumLtd All rights reserved
Figure 1. Library of 12 Synthetic LPS Core Structures
Natural LPS structure immunotype L3 of N. meningitidis (inset) and synthetic LPS core structures from N. meningitidis (1), Yersinia pestis (8, 11), Haemophilus
influenzae (9), Proteus (10), Chlamydia (12), and their truncated derivatives (2–7).
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Defined LPS Inner Core Antigen for N. meningitidisbactericidal activity (SBA) in a gold standard surrogate assay for
in vivo protection against N. meningitidis infections (Plested
et al., 2001, 2003). Human antibodies specific for LPS inner
cores showed bactericidal and opsonic activity as well (Ja¨kelChemistry & Biology 22,et al., 2008; Plested et al., 2001). However, conjugation of detox-
ified LPS to a carrier protein that is required to induce a robust
immune response is not straightforward. Aggregation and low
solubility due to the amphiphilic character of purified LPS38–49, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 39
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incorporation of functional groups for covalent linkage to carrier
proteins are performed on purified LPS prior to conjugation but
generate neoepitopes that may elicit nonspecific antibodies
(Cox et al., 2010a, 2010b; St Michael et al., 2014). Furthermore,
purified LPS offers a limited possibility for antigen refinement due
to its restriction to sequentially expressed LPS core structures
on engineered knockout mutants. In contrast, chemical synthe-
sis offers virtually unlimited structural variability that allows pre-
cise definition and manipulation of the antigen.
We used a combination of chemical synthesis and glycan array
screening to define a highly conserved portion of the LPS inner
core structure as a potential antigen candidate. For that purpose,
a library of species-specific LPS inner core oligosaccharides was
synthesized (Figure 1). Based on glycan array screening of these
synthetic oligosaccharides with human sera, the conserved LPS
inner core structure of all N. meningitidis immunotypes a-D-
GlcNAc-(1/2)-L-a-D-Hep-(1/3)-L-a-D-Hep-(1/5)-a-Kdo (Fig-
ure 1) was chosen for further immunological evaluation. There-
fore, this tetrasaccharide was conjugated to the carrier protein
CRM197, a nontoxic diphtheria toxin variant commonly used for
glycoconjugate vaccines. The resulting glycoconjugate gener-
ated an antibody response against the tetrasaccharide and a
collection of closely related synthetic LPS core analogs in
mice. Binding of serum antibodies to a broad collection of viable
wild-type (wt)N.meningitidis strains expressing diverse immuno-
types demonstrated the accessibility of the LPS inner core on the
bacterial cell surface. The structural requirements of the syn-
thetic antigen to elicit protective antibodies were assessed
with a combination of glycan array, surface plasmon resonance
(SPR), and immunoassays. We report the epitope mapping of
mAbs and polyclonal antibodies specific to the LPS core and
its correlation with binding to viable N. meningitidis strains. Our
approach demonstrates the usefulness of synthetic LPS core
structures in identifying crucial epitopes as a basis for the devel-
opment of an improved synthetic LPS core antigen thatmay elicit
antibodies with broad reactivity to N. meningitidis strains.
RESULTS AND DISCUSSION
Synthesis of LPS Inner Core Oligosaccharides 5 and 6
The LPS inner core oligosaccharides 1–4, 7–10 (Yang et al.,
2012, 2013), 11 (Anish et al., 2013), and 12 (Guo, 2011) were pre-
pared as previously described by relying on de novo and diver-
sity-oriented synthetic strategies (Figure 1). However, synthesis
of disaccharide 6 and trisaccharide 5 can be conducted with less
sophisticated building blocks. L-a-D-Hep-(1/3)-L-a-D-Hep
disaccharide 6 and a-D-GlcNAc-(1/2)-L-a-D-Hep-(1/3)-L-
a-D-Hep trisaccharide 5 were assembled from building blocks
13–15 (Figure 2). Hep building blocks 14 and 15 were prepared
by using our previously developed synthetic procedures (Yang
et al., 2012, 2013). Hep building block 13was accessed by intro-
ducing an N-benzyl-N-benzyloxycarbonylpentyl linker (Mong
et al., 2003; Noti et al., 2006) on the reducing end of Hep interme-
diate 16 that was, in turn, obtained by de novo synthesis (Ohara
et al., 2010). Hep intermediate 16 was converted into the corre-
spondingN-phenyl trifluoroacetimidate (Yu and Tao, 2001, 2002)
17 upon selective anomeric delevulinoylation and N-phenyl tri-
fluoroacetimidate formation (78% yield over two steps). Glyco-40 Chemistry & Biology 22, 38–49, January 22, 2015 ª2015 Elseviersylation of linker 18 with N-phenyl trifluoroacetimidate 17 under
the catalysis of TMSOTf in a mixture of dichloromethane and
ether produced the desired a-linked monosaccharide 19 in
72% yield. In the presence of hydrazine and acetic acid, the O-
Lev group in 19 was selectively removed to afford Hep building
block 13 in 87% yield. The coupling of Hep 14 and 13 promoted
by TMSOTf gave the desired a-(1/3)-linked disaccharide that
was treated with HF, pyridine to afford disaccharide 20 in 65%
yield over two steps. Saponification of the acetyl groups in 20
with sodium methoxide followed by hydrogenolysis over palla-
dium on carbon (Pd/C) provided L-a-D-Hep-(1/3)-L-a-D-Hep
disaccharide 6 in 75% yield over two steps. Coupling of disac-
charide 15 and Hep 13 promoted by TMSOTf in a mixture of
dichloromethane and ether gave the desired a-(1/3)-linked
trisaccharide. Treatment of the newly formed trisaccharide with
thioacetic acid in pyridine allowed separation of trisaccharide
21 from the remaining derivative of monosaccharide 13 at this
step, thus affording acetamide 21 in 72% yield over two steps.
Global deprotection of 21 involved TBDPS cleavage, saponifica-
tion, and hydrogenolysis over Pd/C to provide a-D-GlcNAc-(1/
2)-L-a-D-Hep-(1/3)-L-a-D-Hep trisaccharide 5 (33% yield over
three steps).
Naturally Occurring Human Antibodies Bind Selectively
to Synthetic LPS Inner Core Oligosaccharides
N. meningitidis colonizes the nasopharyngeal mucosa asymp-
tomatically, a state referred to as carriage occurring in 35% of
healthy young adults, and opportunistically invades and infects
exclusively humans (Caugant et al., 2007). Mapping binding pref-
erences of natural antibodies raised by asymptomatic carriers
and infected patients provides direct evidence for their immuno-
genicity in vivo that helps to define the antigenic epitopes. Natu-
rally occurring immunoglobulin (Ig)G and IgM antibodies specific
forDgalE LPS core glycolipid were earlier detected in healthy and
infected persons via ELISA, demonstrating the immunogenicity
of the DgalE LPS core (Plested et al., 2000). To examine whether
antibodies specific for synthetic LPS core structures are present
in humans who have been exposed to N. meningitidis, we per-
formed glycan array screenings of sera from convalescent pa-
tients who recovered from N. meningitidis infection (n = 11),
asymptomatic N. meningitidis carriers (n = 11), and healthy
individuals (n = 15) (Hubert et al., 2013; Figure 3). Glycan array
analysis revealed that IgG antibodies in human sera showed
exclusive binding to meningococcal tetrasaccharide 1 and
trisaccharide 5, while there was only weak binding to trisaccha-
ride 2. Trisaccharide 2 represents a highly conserved LPS inner
core of many Gram-negative bacteria. Low binding to 2,
compared to 1 and 5, indicates the importance of the distal
trisaccharide 5 for antibody recognition of the N. meningitidis
LPS core. Weak binding to the LPS cores of Y. pestis 8,
H. influenzae 9, and bacteria of genus Proteus 10 revealed the
specificity of natural antibodies for N. meningitidis LPS core gly-
cans. The same trend was observed for IgM antibodies (data not
shown). No significant differences between healthy individuals
and convalescent patients or asymptomatic N. meningitidis car-
riers were detected. Discrimination between these groups was
based on mucosal swabs revealing the current N. meningitidis
colonization status of each individual. Possible previous coloni-
zation was not considered. Human sera screening revealed theLtd All rights reserved
Figure 2. Synthesis of Disaccharide 6 and Trisaccharide 5
Synthesis of L-a-D-Hep-(1/3)-L-a-D-Hep disaccharide 6 and a-D-GlcNAc-(1/2)-L-a-D-Hep-(1/3)-L-a-D-Hep trisaccharide 5. Pyr, pyridine; Rt, room temper-
ature; MS, molecular sieves.
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that appear to be highly antigenic.
Immunological Evaluation of Synthetic LPS Core
Tetrasaccharide 1 from N. meningitidis
Based on the results of the human serum antibody screening, the
immunogenicity of synthetic LPS core tetrasaccharide 1 was
tested in a mouse model. Tetrasaccharide 1 was selected over
trisaccharide 5 to elicit antibodies with broader specificities
(Evenberg et al., 1992; Pozsgay et al., 1999). In addition, the
immunogenic potential of charged motifs in oligosaccharide an-
tigens justified the selection of a synthetic target containing a
Kdo moiety (Adamo et al., 2012; Palusiak et al., 2014). Most
carbohydrates are poorly immunogenic and fail to induce long-
lasting memory response. In order to recruit T cell help, we
conjugated 1 to carrier protein CRM197 using the previously
described di-N-succinimidyl adipate (DSAP) spacer (Bro¨ker
et al., 2009, 2011), generating tetrasaccharide 1-CRM197 conju-
gate 22 (Figures S1A–S1C available online) (Anish et al., 2013;
Martin et al., 2013). To investigate the antigenic potential of tet-
rasaccharide 1, three groups of mice (n = 6) were immunizedwith
different doses of conjugate 22 corresponding to 3 mg, 2 mg, and
1 mg of tetrasaccharide 1 in the presence of a human-approved
adjuvant, Alum Alhydrogel (Alum) (Clements and Griffiths, 2002;Chemistry & Biology 22,Figure 4). Mice (n = 6) immunized with an amount of 22 contain-
ing 3 mg antigen 1 formulated in Freund’s adjuvant (FA) were
used as the positive control because of the promotion of strong
carbohydrate-specific immune responses by this adjuvant (An-
ish et al., 2013; Fu et al., 1992; Martin et al., 2013). The control
group (n = 6) was sham-immunized with an equal volume of ster-
ile PBS and showed no anti-tetrasaccharide 1 response. Each
mouse received priming and boosting of 22 formulated with
the respective adjuvant. A dose-dependent anti-tetrasaccharide
1 response was observed in all mice immunized with Alum-
formulated glycoconjugate 22 at day 15 and day 36 (Figure 4).
Antibodies against the carrier protein 28 (Figure S1G) and spacer
moiety 27were also observed (Figure 4). Increased fluorescence
intensities were detected for BSA-[spacer-GlcNAc]16 27
compared to BSA-[spacer-DiMan]21 34 due to GlcNAc binding
antibodies (Figure S1E). A dose of conjugate 22 containing
1 mg tetrasaccharide 1 was sufficient to elicit a carbohydrate-
specific immune response. We observed increased antibody
levels after boosting for all groups immunized with 22, demon-
strating successful recruitment of T cell help (day 36). Further-
more, we were interested in the generation of a long-lasting
memory response. Therefore, mice were left untreated for
224 days until antibody levels subsided before the animals
were reimmunized with one fifth of the priming dose at day38–49, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 41
Figure 3. Human IgG Specific to Synthetic LPS Core 1 and 5 on Glycan Array
Glycan array analysis of IgG antibodies in sera from N. meningitidis-infected convalescent patients (n = 11), asymptomatic N. meningitidis carriers (n = 11), and
healthy individuals (n = 15) against 12 synthetic LPS inner core oligosaccharides.
(A) Representative array scan of patient sera (left) and printing pattern (right).
(B) Quantification ofmean fluorescence intensity (MFI) values for selected LPS cores ofN.meningitidis 1,Y. pestis 8,H. influenzae 9 andProteus 10, and truncated
LPS core trisaccharides 5 and 2. Error bars represent SEM of two spots of two separate arrays. MFI values were compared with two-tailed unpaired t tests.
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Defined LPS Inner Core Antigen for N. meningitidis260 (Figure 4). A robust recall response after reimmunization was
observed at day 267. Overall, the immunization with tetrasac-
charide 1-based glycoconjugate 22 administered with Alum eli-
cited robust primary, secondary, and long-lasting memory IgG
responses and revealed the immunogenicity of this glycan.
Accessibility of Conserved LPS Core Tetrasaccharide 1
on Viable N. meningitidis
On the cell surface of N. meningitidis, tetrasaccharide 1 is pre-
sented as a subcapsular antigen that is modified by several side
chains (Figure 1, inset). To investigate whether antibodies gener-
ated against synthetic tetrasaccharide 1 are able to recognize
the natural LPS core, we performed immunolabeling of heat-inac-
tivated N. meningitidis (27 different strains) with postimmune sera
generated against conjugate 22 administered with FA (hereinafter
referred to as the ‘‘FAgroup’’), as thesemiceproduced the highest
IgG levels against 1. Preimmune sera served as the control.
Confocal fluorescence microscopy showed weak IgG binding for
preimmune sera, while immunolabeling with postimmune sera re-
vealed strong IgG binding toN.meningitidis bacteria visualized by
bright fluorescein isothiocyanate (FITC) fluorescence (Figure 5A).
Fluorescence signals observed on the bacterial surfaces indi-
cated that antibodies generated against synthetic tetrasaccharide
1 recognized the LPS core on heat-inactivated N. meningitidis.
Immunolabeling of the encapsulated N. meningitidis B wt strain
MC58 (used here as a positive control), and its LPS-free DlpxA
mutant was quantified by flow cytometry (Figure S2A). Postim-
mune sera generated against 22 containing 3 mg of antigen 1
formulated with Alum (hereinafter referred to as the ‘‘Alum
group’’), and postimmune sera of the FA group showed significant
binding to MC58 wt compared to MC58 LPS-free DlpxA mutant.
This demonstrates that generated serum antibodies bind to
the LPS core of heat-inactivatedN.meningitidis bacteria. As inac-
tivation may alter the cell-surface structures and expose buried
inner core epitopes, we immunolabeled viable, noninactivated
N. meningitidis strains in an ELISA-based assay. As observed
for heat-inactivated strains, postimmune sera of the Alum group42 Chemistry & Biology 22, 38–49, January 22, 2015 ª2015 Elseviershowed significantly higher binding to viable MC58 wt compared
to LPS-freeDlpxAmutant (Figure 5B) (p = 0.0000028). This obser-
vation demonstrates that the LPS inner core on noninactivated
strains is accessible to antibodies generated against synthetic tet-
rasaccharide 1. Binding to representative strains of all 12 immu-
notypes was observed, revealing the presence and accessibility
of conserved tetrasaccharide 1 by postimmune sera of the Alum
group (Figure 5B). LPS immunotypes differ in length of a chain
as well as modification of HepII with PEtN (3- or 6-position) and/
or Glc. In an earlier immunization study with DgalE mutant ex-
pressing LPS with a PEtN at the 3-position of HepII, the murine
mAb B5 was elicited, which recognized only strains expressing
this particular PEtN modification (Plested et al., 1999). However,
the synthetic tetrasaccharide 1 used in our approach lacks
PEtN modification but elicited antibodies that bound to immuno-
types expressing PEtN modification at the 3-position (immuno-
type L1, L3, L7, or L8) (Verheul et al., 1994) or 6-position (immuno-
type L2, L4, or L6) (St Michael et al., 2009; Weynants et al., 2009)
(Figure 5B). Furthermore, the immunotype L5, which is free of
PEtN modification, was also bound by postimmune sera of the
Alum group. We systematically mapped the epitope recognized
by antibodies on the bacterial surface by testing a collection of
mutated N. meningitidis MC58 strains expressing sequentially
truncated LPS structures (Figure 6A) (Jennings et al., 1995; Kurzai
et al., 2005; Rahman et al., 2001). Postimmune sera of the Alum
group showed significant binding to full-length and to all truncated
LPSs. It is interesting that the Dpgm and DgalE mutants showed
the highest binding compared to other mutants. The LPS core
Dpgm mutant closely resembles the synthetic tetrasaccharide 1
(Figure 1). Increased antibody binding to these mutants is in
accordance with observations made in earlier immunization
studies with detoxified LPS core glycoconjugates that revealed
strongest reactivity to homologous strains (Cox et al., 2010a; St
Michael et al., 2014). The enhanced recognition of Dpgm and
DgalEmutantsmight be the result of optimal exposure and acces-
sibility of the a-D-GlcNAc-(1/2)-[PEtN-3]-L-a-D-Hep-(1/3)-L-
a-D-Hep motif. Furthermore, binding analysis of natural humanLtd All rights reserved
Figure 4. Anti-tetrasaccharide 1-Specific Antibodies in Boosting and Memory Response of Immunized Mice
Glycan array analysis of antibodies in mouse sera collected at days 0, 15, and 36, representing the initial immune responses against tetrasaccharide 1. The
memory response specific for tetrasaccharide 1was assessed at days 260 and 267. Mice immunized with equal volumes of sterile PBS were used as the control
group.
(A) Representative array scans of IgG antibodies in preimmune sera (upper panel) and postimmune sera (lower panel) of a mouse immunizedwith an amount of 22
containing 3 mg tetrasaccharide 1 (3 mg 1 in 22 + Alum). The printing pattern is shown at the right of the scans.
(B) Quantification of mean fluorescence intensity of IgG antibodies in mouse sera specific for tetrasaccharide 1. Error bars represent SEM (n = 6). Relative
response units represent mean fluorescence intensity of each group normalized to background fluorescence.
See also Figure S1D.
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ference to distal trisaccharide 5 (Figure 3). The importance of
a-GlcNAc was proven by the significantly decreased binding
(p = 0.00019) to the DrfaK mutant that lacks this unit (Figure 6A).
For postimmune sera of the FA group, weak but significant
binding to viableMC58wt, truncatedDlst, andDlgtA LPSmutants
was observed (Figure S2C). Similarly to sera of the Alum group,
sera of FA group showed increased binding to Dpgm and DgalE
mutants due to expression of closely related LPS core structures
to tetrasaccharide 1. However, FA group sera did not recognize
further truncated LPS core of DrfaK and DrfaF mutants. Overall
binding to viable N. meningitidis by FA group sera was lower
compared to that of the Alum group. Therefore, FA group sera
were not further considered in the following studies with viable
bacteria.
Postimmune sera of the Alumgroup showed significant binding
toN.meningitidis strains of serogroupsA, B,C,W, Y, X, and E and
a capsule null locus (cnl), a strain lacking the capsule, demon-
strating that LPS core recognition is not influenced by capsule
(Figure S2B). Taken together, the immunolabeling studies with
postimmune sera of the Alum group raised with tetrasaccharide
1 revealed broad binding to various viableN. meningitidis strains.
Binding of Anti-tetrasaccharide 1 Antibodies to LPS
Inner Core of Closely Related Gram-Negative Bacteria
Since most Gram-negative bacteria express LPSs that contain
core structure motifs shared with tetrasaccharide 1, we deter-
mined the specificity of antibody recognition of postimmune
sera to a panel of Gram-negative bacteria, while LPS-free
Gram-positive bacteria served as negative controls (Figure 6B).
No cross-reactivity was observed for closely related N. mucosa
or other Gram-negative and Gram-positive bacteria. Significant
cross-reactivity only occurred to N. lactamica. This finding is inChemistry & Biology 22,accordance with earlier reports wherein mAb B5 generated
against DgalE LPS also cross-reacted with N. lactamica (Plested
et al., 1999). It was shown that the LPS of N. lactamica contains
antigens cross-reacting to meningococcal immunotypes L3, L7,
and L9 (Braun et al., 2004). These results indicate the high spec-
ificity of the anti-tetrasaccharide 1 antibodies to N. meningitidis.
Immunoprotective Effects of Anti-tetrasaccharide 1
Antibodies
Besides their binding to the pathogen, functional antibodies are
required to eliminate bacteria and protect from infection. Two
in vitro assays are currently used to assess the functional activity
of antibodies: the opsonophagocytic activity (OPA) (Ja¨kel
et al., 2008; Plested et al., 2001) and SBA assays. The gold
standard test to detect N. meningitidis lysis in the presence of
complement is the SBA assay that correlates with immunopro-
tection (Plested et al., 2001). For the SBA measurement of
N. meningitidis B, a human complement source, typically serum,
should be used because increased bactericidal titers were
observed in the presence of rabbit complement (Santos et al.,
2001; Zollinger and Mandrell, 1983). In contrast, SBA of
N. meningitidis serogroup C can be conducted with rabbit
complement source. Thus, we performed our SBA assay with
N. meningitidis serogroup C expressing homologous immuno-
type L3 wt (WUE2120) and the corresponding truncated Dpgm
mutant (WUE2420). Despite the broad and specific recognition
of N. meningitidis strains by serum antibodies, no serum-depen-
dent bactericidal activity was detected (Figures S3A–S3C). The
OPAmeasures antibody opsonization ofN.meningitidis that trig-
gers uptake into phagocytic cells such as neutrophils, resulting
in protection against bacteremia. The postimmune sera of the
Alum group showed a tendency toward higher OPA titers for
MC58 wt (p = 0.08; Figure S3D).38–49, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 43
Figure 5. Immunolabeling of Heat-Inactivated and Viable N. meningitidis with Tetrasaccharide 1-Specific Mouse Sera
(A) Confocal fluorescence microscopy images of heat-inactivated N. meningitidis B strain DE8759 with pre- and postimmune sera of the FA group. Bacteria-
bound antibodies were detected with secondary anti-mouse IgG-FITC antibody (green). DNA staining with DAPI (blue) was used as the counterstain. Differential
interference contrast (DIC) images are shown in the upper right.
(B) Binding of postimmune sera of the Alum group and control group to viable N. meningitidis strains detected by an ELISA-based assay. One representative
strain of each of the 12 immunotypes was immunolabeled. The N. meningitidis DlpxA mutant that lacks LPS was used as negative control. Bacteria-bound
antibodies were detected with a secondary anti-mouse IgG-HRPO antibody. Fold changes in mean optical density 450 nm of bacteria incubated with pooled
postimmune serum from the Alum group, with respect to control group, are shown as bars. Representative results from three independent experiments withmean
of three replicates are shown. Error bars represent SEM. *p < 0.05, inferred by two-tailed unpaired t tests against the DlpxA strain.
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bodies revealed IgG1 as the main isotype in Alum serum, fol-
lowed by a small IgG2a portion (Figure S4A), in accordance
with the fact that Alum is mainly a Th2-skewing adjuvant that pri-
marily induces IgG1 antibodies in mice (Bungener et al., 2008).
Isotypes IgG3 and IgG2a are described to promote SBA and
OPA (Michaelsen et al., 2004). The absence of isotype IgG3
and the low amount of isotype IgG2a may explain the lack of
SBA and low OPA. Improved formulation strategies using
approved Th1-skewing adjuvants that force a class switch to-
ward IgG2a and IgG3 may elicit protective antibodies against
N. meningitidis infection (Baudner et al., 2009; Lin et al., 2004).
Determination of Conserved Immunogenic Epitope of
Anti-LPS Inner Core Antibodies
Although we observed broad binding of the serum antibodies to
viable N. meningitidis strains, the absence of functional anti-
bodies suggests that presentation of the LPS core requires
improvement. We aimed to determine the essential structural re-
quirements of the LPS core antigen that may elicit protection us-
ing glycan array analysis and SPR. Postimmune sera of the Alum
and FA groups showed similar binding preferences against 12
synthetic LPS core structures presented on a glycan array (Fig-
ures 7A and 7B). Three truncated versions of tetrasaccharide
1, compounds 2–4were recognized, whereas no cross-reactivity
for conserved LPS core of genus Chlamydia 12 was observed,
demonstrating specific binding to mono-a-Kdo 4 and L-a-D-
Hep-(1/5)-a-Kdo components. This observation explains
the cross-reactivity to the related LPS cores of Y. pestis 8,
H. influenzae 9, and Proteus 10, representing variants of struc-
ture 2, a conserved LPS core of many Gram-negative bacteria.
In contrast, LPS core only consisting of Hep moieties such as
di-Hep 6, mono-Hep 7, and tri-Hep 11 were not recognized by
the serum antibodies, indicating a prominent role of the charged
Kdo in antibody-glycan interactions. Unlike the natural human
serum antibodies that bind preferentially to the distal trisaccha-44 Chemistry & Biology 22, 38–49, January 22, 2015 ª2015 Elsevierride 5 (Figure 3), the mouse serum antibodies generated against
tetrasaccharide 1 predominantly recognize the Kdo-containing
structures (Figure 7B). Earlier reports on anti-LPS core mAbs
showed that mouse germline antibodies harbor an inherited
binding pocket specific for Kdo (Nguyen et al., 2003). In addition,
we have observed a specific antibody response in an immuniza-
tion study with the unconjugated tetrasaccharide 1 (Figure S5).
Furthermore, an immunization approach with detoxified LPS
conjugated to CRM197 showed that Kdo disaccharide-b-GlcN
of the conjugate seems to be somewhat immunodominant
(Cox et al., 2010a). In summary, glycan array studies identified
Kdo as the immunodominant residue in antigen 1.
Binding specificities of polyclonal sera may be due to contri-
bution of multiple antibodies. To deduce antibody specificities
at the molecular level, we generated tetrasaccharide 1-specific
mAb from a mouse via hybridoma technique (Anish et al.,
2013; Ko¨hler and Milstein, 1975). Two mAbs, termed 1A5 1G1
and 1B6 4E1, were purified to homogeneity (Figure S6A). In
glycan array analysis, mAb 1A5 1G1 recognized all oligosaccha-
rides interacting with polyclonal sera except trisaccharide 5 (Fig-
ures 7C and 7D).mAb 1A5 1G1 has a binding preference for Kdo-
containing epitopes explaining the cross-reactivity to related
LPS cores 8–10 and truncated LPS cores 2–4. mAb 1B6 4E1 pre-
dominantly binds to tetrasaccharide 1, and thereafter to trisac-
charide 2, causing cross-reactivity to related LPS cores 8–10.
To further elucidate binding profiles, we determined the binding
affinities to the LPS cores 1–5 by SPR (Figures S6B–S6G). For
mAb 1A5 1G1, dissociation constant (KD) values in the lowmicro-
molar range for LPS cores 1–4 were detected with decreasing
affinity to truncated LPS cores 2–4 (Table S1). No detectable
binding was seen for distal trisaccharide 5 (data not shown).
Binding curves of mAb 1A5 1G1 reached steady state only for
a-Kdo 4 (Figure S6E). SPR analysis confirmed Kdo as the pre-
dominant epitope component of mAb 1A5 1G1. For the interac-
tion of mAb 1B6 4E1with tetrasaccharide 1, KD values in the high
micromolar range were observed (Figures S6F and S6G). NoLtd All rights reserved
Figure 6. Immunolabeling of Viable N. meningitidis LPS Core Mutants, and Gram-Negative and Gram-Positive Bacteria, with Tetrasacchar-
ide 1-Specific Mouse Sera of the Alum Group
(A) Binding of postimmune sera of the Alum group and control group to viable N. meningitidis (immunotype L3) MC58 mutants expressing truncated LPS
measured by ELISA-based assay.
(B) Binding of postimmune sera of the Alum and control groups to viable related Neisseria species, Gram-negative and Gram-positive bacteria measured by an
ELISA-based assay. Detection of bound antibodies was performed with secondary anti-mouse IgG-HRPO antibody. Fold change inmean optical density 450 nm
of the Alum group, with respect to control group, is plotted. Average of three independent experiments with mean of three replicates is shown. Error bars
represent SEM. *p < 0.05, two-sided unpaired t tests against DlpxA.
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Defined LPS Inner Core Antigen for N. meningitidisconcentration-dependent binding was observed for trisaccha-
ride 2 and a-Kdo 4, disclosing selective binding of 1B6 4E1 to
tetrasaccharide 1 (data not shown). The reactivity of theseChemistry & Biology 22,mAbs suggests that immunization with tetrasaccharide 1 elicited
antibodies strongly binding to Kdo-containing structures with
insignificant binding to the crucial distal trisaccharide 5. In38–49, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 45
Figure 7. Specificity of Mouse Sera of the Alum and FAGroups and of Tetrasaccharide 1-SpecificmAbs 1A5 1G1 and 1B6 4E1 toward 12 Syn-
thetic LPS Core Structures Inferred by Glycan Array
(A–D) Representative array scan of sera from the Alum group (A, left) of mAbs 1A5 1G1 (C, left) and 1B6 4E1 (C, right) and the printing pattern (A, right) are
depicted. Quantification of mean fluorescence intensity of postimmune sera (B) and mAbs (D) are also shown. Error bars represent SD of two spots of two
separate arrays, respectively.
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Defined LPS Inner Core Antigen for N. meningitidiscontrast to the postimmune sera, both mAbs did not recognize
the LPS core on viable N. meningitidis strains. The broad
cross-reactivity to synthetic LPS cores observed on the glycan
arrays may be caused by the presentation of Kdo residues via
their pentyl amino linker on the array surface. On the contrary,
accessibility to Kdo may be restricted on natural bacterial sur-
faces due to close proximity to the outer membrane. Moreover,
postimmune serum antibodies bound to compound 5, whereas
the mAbs did not (Figure 7). Thus, exposure of distal trisaccha-
ride 5 on the surface of N. meningitidis most likely permits bind-
ing of postimmune sera to the LPS core. In another immunization
approach, BSA conjugates with different antigen loadings of the
synthetic oligosaccharides from Vibrio cholerae O1 Inaba O-
polysaccharide elicited a comparable level of antibodies with
limited protection (Meeks et al., 2004).
To further refine the structural requirements for LPS recogni-
tion by antibodies, we tested mAb B5 raised against LPS of
DgalE mutant (a kind gift from Dr. A.D. Cox). mAb B5 showed
SBA and reacted against severalN.meningitidis strains express-
ing LPS with PEtN at 3-position of HepII (Plested et al., 1999,
2003). In a glycan array screening, mAb B5 did not bind to any
synthetic LPS core, probably due to the absence of a PEtNmodi-
fication (Figure S7A). To further delineate the immunodominance
of Kdo, we tested the binding of our antibodies against isolated
and delipidated DgalE LPS that was immobilized on an array
slide via an adipic acid dihydrazide (ADH) spacer. This immobi-
lization destroyed the a-Kdo motif due to derivatization at its46 Chemistry & Biology 22, 38–49, January 22, 2015 ª2015 Elsevieranomeric position by hydrazide group with predominant
b-configuration (Lee and Shin, 2005). mAb B5 bound to immobi-
lized DgalE LPS core, whereas our mAbs did not (Figures S7B
and S7C). mAb B5 binds to the LPS core via the trisaccharide
5 derivative with an additional PEtN on HepII and Glc on HepI
(Plested et al., 1999), independent of the a-Kdo motif. While
postimmune sera of the FA group showed weak reactivity to im-
mobilized DgalE LPS core compared to mAb B5, postimmune
sera from the Alum group did not show any binding to DgalE
LPS core (Figures S7B and S7C). This effect may be explained
by higher avidity of tetrasaccharide 1-specific antibodies raised
by the Th1-skewing FA compared to Th2-skewing Alum (Figures
S4B and S4C). Accordingly, higher signal intensities were gained
for FA sera compared to Alum in glycan array screening on syn-
thetic LPS core structures (Figures 7A and 7B).
Based on glycan array screening, SPR, and bacterial immuno-
labeling, we infer that the trisaccharide motif represented by
5 is the crucial component of an LPS core antigen against
N. meningitidis. This distal LPS core 5 was recognized by post-
immune sera produced against synthetic tetrasaccharide 1, but
antibody levels were low compared to that raised against Kdo-
containing structures 1–4 and 8–10. Moreover, human sera pre-
dominantly recognize structure 5 (Figure 3). Furthermore, bacte-
ricidal mAb B5 bound only weakly to the N. meningitidis DicsB
mutant expressing tetrasaccharide 1derivativewith an additional
PEtN on HepII (identical phenotype to Dpgm) (Plested et al.,
1999), substantiating the hypothesis that distal parts of the LPSLtd All rights reserved
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tivity of mAbB5 against PEtNmodification onHepII, it only bound
to 76% of N. meningitidis B strains expressing this specific PEtN
but not to strains with alternative modifications (Plested et al.,
1999). Avoidance of LPS core variants such as PEtNmodification
and Glc residue on HepII may recruit more broadly reactive
antibodies. Thus, by leaving out Kdo, the highly conserved LPS
core trisaccharide 5might already be sufficient to raise a broadly
protective immune response. Furthermore, via addition of con-
served Glc to HepI in 5, an enlarged, branched, and more sur-
face-exposed LPS core a-D-GlcNAc-(1/2)-L-a-D-Hep-(1/3)-
[b-D-Glc-(1/4)]-L-a-D-Hep is formed that may elicit both broad
cross-reactivity to N. meningitidis and bactericidal activity. This
assumption is substantiated by the broadly cross-protective
mAb WN1 222-5, which binds to the LPS inner cores of E. coli
and Salmonella. The 4-phosphate groups on the branched HepII
and the HepIII side chains were identified as the minimal struc-
tural determinants for high-affinity binding to these LPS inner
core structures. This finding demonstrates the relevance of
branched structures (Mu¨ller-Loennies et al., 2007).
Currently, efforts are underway to redesign the synthetic anti-
gen to generate adequate antibody levels to distal parts of the
N. meningitidis LPS inner core with functional activity. Here, we
have shown the power of synthetic LPS core oligosaccharides
in defining a universal antigen candidate for N. meningitidis. A
T cell-dependent antibody response specific to conserved LPS
core 1was elicited in mice. The immunodominant a-Kdo residue
accounted for the lack of functional antibodies. In contrast, the
distal trisaccharide 5mediates specific recognition of the natural
LPS core onN. meningitidis. Based on our findings, an improved
synthetic LPS core compared to compound 5 is currently being
explored as a broadly protective antigen against N. meningitidis.
SIGNIFICANCE
Designing a synthetic carbohydrate antigen candidate in-
volves the choice of the optimal structure to confer protec-
tion. Today, antigen identification is an iterative process
involving trial-and-error experiments. Here, we report
progress in this process using a highly conserved LPS core
structure of N. meningitidis as an example. Antigenicity and
immunogenicity of synthetic LPS core oligosaccharides
were evaluated using glycan arrays, in vivo immunogenicity
studies, SPR, and in vitro surrogate assays for functional bac-
teria-killing antibodies. In combination with the epitopemap-
ping of earlier described protective mAb B5, structural infor-
mation of a potential, broadly reactive LPS core epitope was
inferred. Glycan array screening of patient sera revealed an-
tibodies specific todifferent LPS inner core structures.Based
on these screenings, a tetrasaccharide was selected for
immunological evaluation in mice and, therefore, conjugated
to carrier protein CRM197. This glycoconjugate yielded LPS
core-specific robust IgG and memory responses. Serum
antibodies bound to numerous viable N. meningitidis
strains. The immunodominant Kdo moiety contained in this
tetrasaccharide elicited highly affine antibodies against
Kdo-containing oligosaccharide but failed to bind to
N. meningitidis bacteria. We identified the distal part of the
LPS core as the crucial unit to recruit antibodies that areChemistry & Biology 22,broadly reactive to N. meningitidis expressing diverse LPS
immunotypes. Based on our results, we propose an
improved, highly conserved LPS core tetrasaccharide a-D-
GlcNAc-(1/2)-L-a-D-Hep-(1/3)-[b-D-Glc-(1/4)]-L-a-D-
Hep to generate antibodies that may unify broad reactivity
and bactericidal activity against N. meningitidis.
EXPERIMENTAL PROCEDURES
Chemical Synthesis
A detailed description of experimental procedures and characterization
of synthetic compounds are available in Supplemental Experimental
Procedures.
Human Sera
Convalescent sera used have been published recently (Hubert et al., 2013).
Sera from healthy individuals carrying or not carrying N. meningitidis were ob-
tained from human volunteers, with permission of the Ethics Committee of the
Medical Faculty of the Julius-Maximilians-University.
Ethics Statement
Animal experiments were performed in accordance with the German regula-
tions of the Society for Laboratory Animal Science and the European Health
Law of the Federation of Laboratory Animal Science Associations. All efforts
were made to minimize the suffering of the animals.
Immunization Studies and Evaluation of Immune Response Using
SPR and Microarray
Glycoconjugate of CRM197 and amino-linked antigen was produced, charac-
terized, and immunized in BALB/c mice in a dose- and formulation-dependent
manner (Martin et al., 2013). Splenocytes of a mouse with the highest antibody
titer (FA group) were used to generate mAbs via the hybridoma technique (An-
ish et al., 2013; Ko¨hler and Milstein, 1975). Specificities of serum antibodies
and purified mAbs were analyzed by glycan array screening. A glycan array
of synthetic compounds was prepared, and antibody samples were incubated
as described elsewhere (Martin et al., 2013). For immobilization of purified gly-
cans, slides weremodified as reported elsewhere (Lee and Shin, 2005). Affinity
of direct immobilizedmAbs to solubilized glycans and binding ofmouse sera to
immobilized glycans was analyzed by SPR.
Immunolabeling Studies of Bacteria and Functional Activity Test
Staining of bacteria with mAb and polyclonal sera was performed as described
elsewhere (Anish et al., 2013). Antibodies bound to viable bacteria were
detected via secondary goat anti-mouse IgG (H+L)-HRPO antibody, and
readout was accomplished at 450 nm in a microplate reader. Antibodies
bound to inactivated bacteria were detected by appropriated fluorescent-
labeled secondary antibody and measured by flow cytometry or confocal
fluorescence microscopy. SBA (Elias et al., 2013) and OPA (Hazenbos et al.,
1994; Rodrı´guez et al., 2001) of sera were tested as described elsewhere.
For a detailed description, please refer to the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information including Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2014.11.016.
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